- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about CRSP
Recent news which mentions CRSP
From InvestorPlace
With FDA Submission For Sickle Cell Gene Therapy, Bluebird Bio Can Potentially Have 3 Approved Products By 2023
April 24, 2023
From Benzinga
The Best Stocks to Invest $20,000 in Right Now
April 23, 2023
From Motley Fool
Buy the Dip: 2 Top Stocks to Snatch Up Now
April 23, 2023
From Motley Fool
3 Stocks With Huge Catalysts on the Way
April 22, 2023
From Motley Fool
2 Growth Stocks That Could Keep Growing for Decades
April 21, 2023
From Motley Fool
Better Big Biotech Buy: Biogen vs. Vertex
April 20, 2023
From Motley Fool
The Top 3 Biotech Stocks to Watch in 2023
April 20, 2023
From InvestorPlace
Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names
April 20, 2023
From Benzinga
3 High-Growth Biotech Stocks Poised for Success in 2023
April 18, 2023
From InvestorPlace
The Top Healthcare Stocks to Buy With $100
April 18, 2023
From Motley Fool
Why CRISPR Therapeutics Stock Is Marching Higher Today
April 17, 2023
From Motley Fool
Why Shares of Editas Medicine Rose Monday
April 17, 2023
From Motley Fool
Better Growth Stock: Axsome vs. CRISPR Therapeutics
April 16, 2023
From Motley Fool
Is CRISPR Therapeutics Stock a Buy Now?
April 14, 2023
From Motley Fool
Tickers
CRSP
From InvestorPlace
Why Are Gene-Editing Stocks CRSP, EDIT, NTLA Stock Up Today?
April 13, 2023
From InvestorPlace
CRISPR Therapeutics Is an Interesting 'Gene Editing Play for 2023' With Significant Upside, Says Analyst
April 13, 2023
Tickers
CRSP
From Benzinga
$2M Price Tag for Sickle Cell Gene Therapies Could Be Cost-Effective Under Certain Scenarios, Finds ICER Analysis
April 13, 2023
From Benzinga
From Benzinga
Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday
April 13, 2023
From Benzinga
2 Nasdaq Growth Stocks That Are Screaming Buys in April
April 13, 2023
From Motley Fool
These Up-and-Coming Stocks Are Screaming Buys Right Now
April 13, 2023
From Motley Fool
Could This Move Make Vertex's Next Blockbuster Even Bigger?
April 12, 2023
From Motley Fool
From Benzinga
CRISPR Stock: Bull vs. Bear
April 08, 2023
From Motley Fool
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.